OBJECTIVES: The objective of this study is to assess and compare the characteristics of relapsing remitting multiple sclerosis patients taking Fingolimod capsules or Teriflunomide tablets.  METHODS: A large US administrative retrospective claims database was used to identify patients diagnosed with RRMS and were prescribed Fingolimod or Teriflunomide between January 2010 and December 2012 were included in the study. All patients were ≥ 18 years of age and continuously enrolled in the same health plan for a year. Descriptive statistics and chi-square tests were performed on the data and statistical significance level was set a priori at 0.05. RESULTS: There were a total of 3,102 patients on Fingolimod and 114 on Teriflunomide during the study period. Of these, more than 70% of the patients in both the groups were females (75.9% vs 73.7%, p=0.595). Fingolimod patients were younger than Teriflunomide patients (46.54±10.28 vs 48.86±9.86 years, p=0.018). The majority of the patients were in the 40 to 65 years age group (71.1% vs 80.7%, p=0.083). Approximately, one third of patients in both the groups were from East (26.1% vs 31.6%), South (34.7% vs 26.3%) and Midwest (33.2% vs 32.5%) regions with no significant difference between them (p=0.117). There were more number of patient’s prescription was on health plan non-formulary status (40.6% vs 41.2%) than formulary status (32.7% vs 28.1%). Majority of the patients were under group coverage (58.1% vs 61.4%, p=0.771) and were diagnosed with mental health problems (56% vs 54.4%, p=0.061). Fingolimod patients received more number of days of supply than Teriflunomide (31.59±13.65 vs 29.44±8.8 days, p=0.048). There was no significant difference in the number of years patients continuously enrolled in the same health plan between the two groups (4.59±2.48 vs 4.45±2.32 years, p=0.535). CONCLUSIONS: Teriflunomide patients were older and received more number of days of supply than Fingolimod patients.